知镜 Cognispect · 医学文献与研究工作台

Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group.

Gulati R, Suresh K, Psutka SP, Taylor JMG, Owens L, Tsodikov A, Walter LC, Etzioni R.
Cancer · 2026-11-01 · PMID 43018390

文献摘要

Background Prostate-specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis-diagnosis that would not occur during a man's lifetime without screening-particularly in older men and those with life-limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long-term harms and benefits have not been estimated. Methods Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50-70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity-adjusted life tables. Results By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI-targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7-3.1 at age 72 years to 4.5-5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6-10.2 at ages 72 to 11.3-12.6 at 76 years. Conclusions Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life-limiting comorbidities compared with age-matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。